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ABSTRACT
Objectives The anti- Mullerian hormone (AMH) test has 
been promoted as a way to inform women about their 
future fertility. However, data consistently show the test 
is a poor predictor of natural fertility potential for an 
individual woman. As fertility centre websites are often a 
primary source of information for reproductive information, 
it is essential the information provided is accurate and 
reflects the available evidence. We aimed to systematically 
record and categorise information about the AMH test 
found on Australian and New Zealand fertility clinic 
websites.
Design Content analysis of online written information 
about the AMH test on fertility clinic websites.
Setting Accredited Australian and New Zealand fertility 
clinic websites.
Methods Data were extracted between April and June 
2020. Any webpage that mentioned the AMH test, 
including blogs specifically about the AMH test posted 
since 2015, was analysed and the content categorised.
Results Of the 39 active accredited fertility clinics’ 
websites, 25 included information about the AMH test. 
The amount of information varied widely, and embodied 
four overarching categories; (1) the utility of the AMH 
test, (2) who the test is suitable for, (3) possible actions 
in response to the test and (4) caveats and limitations of 
the test. Eight specific statements about the utility of the 
test were identified, many of which are not evidence- 
based. While some websites were transparent regarding 
the test’s limitations, others mentioned no caveats or 
included persuasive statements actively promoting the 
test as empowering for a range of women in different 
circumstances.
Conclusions Several websites had statements about 
the utility of the AMH test that are not supported by the 
evidence. This highlights the need for higher standards for 
information provided on fertility clinic websites to prevent 
women being misled to believe the test can reliably predict 
their fertility.
INTRODUCTION
A woman’s fertility declines with age, due to 
the reduction in the quality and quantity of her 
eggs over time.1 In women, the anti- Mullerian 
hormone (AMH) is exclusively produced by 
granulosa cells of ovarian follicles during the 
early stages of their development.2 AMH levels 
can be measured by a blood test, giving an 
indication of ovarian reserve, or the number 
of eggs remaining in the ovaries. In theory, 
higher levels of AMH indicate the presence of 
more eggs and higher fertility potential and 
low levels indicate that there are few eggs left 
and the woman is approaching menopause. 
Menopause typically occurs at approximately 
50 years of age.3 However, loss of ovarian 
reserve is accelerated in approximately 10% 
of women leading to premature menopause 
and loss of fertility potential before the age of 
40 years.4 The AMH test has been promoted 
as a way for women to find out how much 
longer they have to achieve pregnancy or how 
likely it is that pregnancy could be achieved at 
all,5 potentially encouraging proactive family 
planning and preventing childlessness caused 
by age- related infertility.6 Public interest in 
AMH testing is also increasing with the rise 
of elective egg freezing in women concerned 
about age- related fertility decline.7 8
Strengths and limitations of this study
 ► First study to robustly and systematically assess 
publicly available anti- Mullerian hormone (AMH) test 
information on fertility clinic websites.
 ► Two researchers independently assessed all the 
extracted information about the AMH test, with any 
inconsistencies resolved with an additional member 
of the study team.
 ► Only written content was assessed (eg, videos were 
excluded), potentially missing relevant information 
on the AMH test.
 ► Website content can change over time, meaning that 
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While the AMH test may be valuable in assisted repro-
ductive technology treatment (ART) management 
through indicating potential ovarian response and 
enabling personalised dose selection in stimulation proto-
cols,9 10 it has limited predictability of live birth rates in 
both ART11 12 and spontaneous conception settings.13–15 
In addition, while a low AMH level may reflect a quan-
titative decline in ovarian reserve, there is currently no 
consensus on the level which defines a depleted ovarian 
reserve. Indeed, pregnancy can still occur even at unde-
tectable AMH levels, especially in young women.2 6 16 The 
AMH test is therefore not a reliable measure of fertility 
potential.13 It can also give false readings for women 
with polycystic ovary syndrome (PCOS) or who use oral 
contraceptives.17 The American College of Obstetricians 
and Gynaecologists recently released a statement against 
the use of AMH in women without a diagnosis of infer-
tility as it is not supported by the evidence.18 Despite this, 
some fertility specialists and researchers19 have suggested 
that women in their late 20s have the test at regular 
intervals to monitor their fertility potential. In addition, 
online companies in countries such as the USA, Australia 
and the UK are now selling the test direct- to- consumers 
outside of clinical settings,7 offering women estimates of 
their fertility potential based on the results of the test. In 
Australia, AMH testing can occur in several ways, although 
women are predominantly referred by their general prac-
titioners (GPs) or fertility specialists to get the test from 
pathology laboratories or fertility clinics with in- house 
pathology. The test is not covered by Australia’s universal 
health scheme and has out- of- pocket costs.
Fertility clinic websites along with social media are 
primary sources for women seeking reproductive infor-
mation,20 such as egg freezing.21 When ‘AMH test’ or 
‘egg timer test’ is entered into the Google search engine, 
fertility clinic websites are among the first websites to 
appear. In Australia and New Zealand, fertility clinics 
must be accredited by the Reproductive Technology 
Accreditation Committee (RTAC).22 The RTAC Code 
of Practice states that clinics ‘…must provide patients 
with information that is accurate, timely, in formats and 
language appropriate to the patient…’.22 Considering the 
popular narrative that the AMH test can predict fertility, 
the aim of this study was to systematically record and cate-
gorise any written information about the AMH test found 
on Australian and New Zealand fertility clinic websites.
METHOD
Setting
Accredited fertility clinics in Australia and New Zealand 
were identified from the list of accredited practices on the 
Fertility Society of Australia’s website.23 The websites of 
those clinics were accessed between April and June 2020. 
All webpages that mentioned the AMH test, including 
posts or blogs specifically about the AMH test which had 
been posted since 2015 were scrutinised. Analysis was 
restricted to written context (ie, videos and non- text data 
were excluded). Any webpages described as being specifi-
cally for clinicians (eg, GPs) were also excluded. Websites 
that did not mention the AMH test were excluded from 
further analysis.
Study design
A content analysis of the information on fertility clinic 
websites about the AMH test was conducted. Content 
analysis is a widely used analysis method which combines 
qualitative and quantitative methods to analyse text data, 
allowing the content and frequency of categories to be 
reported.24 Given the uncertain evidence about the utility 
of the AMH test, we aimed to systematically identify and 
categorise the statements made about the utility of the 
AMH test and related information. This method has previ-
ously been used to assess claims made on fertility clinic 
websites about the effectiveness of different treatments.20 
The study team included public health researchers (TC, 
BN, SL, KH and KM), a general practitioner and clinical 
epidemiologist (JD), a registered nurse (KH) and fertility 
specialists (BWM and DL).
Patient and public involvement
No patients or public were involved. The data were 
derived from publicly available information on Australian 
and New Zealand fertility clinic websites.
Analysis
The analysis involved an iterative process with five 
members of the study team. After the number of eligible 
fertility clinic websites were ascertained and the data 
were extracted by one researcher (TC), content analysis 
was used to map out the areas of content that emerged 
and record and categorise the statements made about 
the AMH test, as well as additional observations. First, 
two researchers (TC and BN) independently reviewed 
information about the AMH test on 20 websites each to 
become familiar with the content and develop a list of 
recurring codes and themes. These codes and themes 
were discussed with a third researcher (SL) and informed 
an initial coding framework. All contents were then 
coded independently by two researchers (TC and SL) 
into the framework to ensure rigour. Further revisions 
to the framework were discussed and made as required 
during coding. The level of agreement between the two 
coders was tested using Cohen’s kappa and indicated a 
strong level of agreement (κ=0.83). Any inconsistencies 
in coding were then discussed and resolved, with a third 
researcher (BN) involved to come to a final agreement. 
Descriptive statistical analysis was used to calculate the 
frequency of each code, and quotes were chosen to illus-
trate findings.
RESULTS
Of the 41 accredited fertility clinics listed on the Fertility 
Society of Australia’s website, two had merged with other 
fertility clinics, resulting in 39 eligible clinic websites. 
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The number of web pages with content relating to the 
AMH test varied widely across websites from 0 up to 12 
pages (mean: 3.4 webpages per clinic website). Of the 39 
eligible websites, 14 (36%) did not mention the AMH test 
at all and 8 (21%) only listed the test or gave a very brief 
description of the test, which did not include any addi-
tional information such as potential benefits or limita-
tions. The 14 websites that did not mention the AMH test 
were excluded from further analysis (see figure 1).
Information about the AMH test on the remaining 25 
clinic websites was organised into four overarching cate-
gories; statements about (1) the utility of the AMH test, 
(2) who the test is suitable for, (3) possible actions in 
response to the test and (4) statements reflecting caveats 
and limitations of the test. The overarching categories 
and their affiliated statements, quotes illustrating each 
statement and proportions of clinic websites containing 
each statement are shown in table 1. In addition, two 
patterns of observations arose when analysing the data. 
These included the use of persuasive language and 
contradictory information within and across websites.
Statements about the utility of the AMH test
Eight specific statements about the utility of the test were 
identified, with 19 of the 25 websites listing at least one 
of these. The most common statement made about the 
usefulness of the test was that it is an indicator of ovarian 
reserve, or the number of eggs in the ovaries (76%; 
table 1). Other recurring statements included that the 
test indicates response to fertility treatment [eg, number 
of eggs collected (n=6) or vague treatment success state-
ments (n=3) for example, ‘…a good predictor of IVF success’; 
36%], assesses women’s future fertility potential (eg, how 
many fertile years ahead; 36%) or determines women’s 
current fertility status (28%).
Statements about who the test is suitable for
The test was recommended for a range of women in 
different circumstances and settings, including those 
undergoing assisted reproduction, women who were 
curious about their ovarian reserve and women who 
wanted to know their current and future fertility poten-
tial. The most common recommendations were for 
women considering fertility treatment (48%), women 
with risk factors for reduced fertility (eg, family history of 
premature ovarian failure, women who have had chemo-
therapy, ovarian tumour, endometriosis; 36%) and for 
women planning pregnancy, now or in the future (32%).
Statements about possible actions in response to the result of 
the test
Several websites included statements about possible 
actions in response to the result of the test, with the most 
common being that the test results can inform women 
when to access fertility treatment (40%), assist with repro-
ductive life planning (36%) and inform when to under-
take elective egg freezing (28%).
Stated caveats and limitations of the AMH test
Some websites had statements reflecting caveats or limita-
tions of the test. The most commonly stated limitations 
were that the test is an indicator of egg quantity not 
quality (36%), it does not predict chance of conceiving 
or having a live birth (32%), that age is still the most 
important factor for fertility (20%) and that the results 
can be artificially lower or higher in certain women, such 
as women who are heavy exercisers, are on the contracep-
tive pill, have PCOS or are very young (20%).
Additional observations
Use of persuasive language
Some websites used persuasive language and assertions 
that actively promoted the test. The most common was 
adding a motivation or rationale for having the test 
(44%), such as stating ‘Information is power and lets you 
take charge of your fertility’. Some also communicated the 
growing popularity and demand for the test (eg, ‘more and 
more women are seeking reassurance about their ability to repro-
duce’; 8%) or emphasised the convenience of the test (eg, 
‘a simple blood test’; 44%).
Confusing statements and contradictions
There were also a number of contradictions in the infor-
mation provided across the websites. These included 
contradicting statements about whether the AMH test can 
(n=2) or cannot predict menopause (n=1), is an indicator 
(n=1) or is not an indicator of egg quality (n=9), whether 
the results need to be interpreted by a specialist (n=2) 
or by a GP (n=3), and whether the test is reliable (n=6) 
or can be artificially lower when using oral contracep-
tion (n=5). There was even conflicting, ambiguous and 
confusing statements within the same website on three 
of the websites (12%), with the most common being 
whether or not the blood sample can be taken while using 
oral contraception and whether the test assesses women’s 
fertility (eg, ‘…not a measure of fertility but an important tool 
in assessing potential fertility’ and then in the next para-
graph ‘an AMH test can assess your current fertility’).
Figure 1 Flow diagram of accredited fertility clinic websites 
included in the current study. AMH, anti- Mullerian hormone, 
FSA, Fertility Society Australia
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DISCUSSION
This study systematically recorded and categorised infor-
mation about the AMH test found on Australian and 
New Zealand fertility clinic websites. The information 
provided was highly variable across the websites, from 
providing none or minimal information on the AMH test 
to providing extensive information about the test. Some 
websites were found to be very transparent and upfront 
regarding the test’s limitations, while others did not 
mention limitations or included persuasive statements 
actively promoting the test (eg, promoting empower-
ment, proactive decision- making) for a wide range of 
women in different circumstances. In addition, despite 
some websites containing substantial information about 
the test, it was often disjointed and spread across several 
pages; therefore comprehensive information may be 
difficult for women to find in one place. There were also 
several confusing or unclear statements, as well as contra-
dictions within and across websites.
Importantly, while a number of statements about the 
utility of the test were made across a number of websites, 
few are supported by high- level evidence. Statements 
for which there is some supporting evidence include 
the AMH test being an indicator of ovarian reserve10 25 
in terms of egg quantity and it being associated with the 
number of eggs obtained in an in vitro fertilisation (IVF) 
cycle,9 26 27 although large variation in ovarian response 
remains unexplained.27 Statements with mixed evidence 
include low AMH levels indicating increased risk of 
miscarriage.28 29 There is preliminary evidence that high 
levels of AMH indicate PCOS,30 31 however more research 
is needed to confirm this and current PCOS guidelines 
recommend against using AMH as a diagnostic tool.32 
Statements refuted by existing evidence include the test 
being able to predict a woman’s future fertility potential 
or current fertility status,13–15 33 or identifying a woman 
at risk of early menopause.6 Furthermore, it is important 
to note that although the AMH may be associated with 
outcomes at a population level, this does not mean it has 
predictive value for individuals. For example, while the 
AMH appears to be associated with age of menopause at 
a population level, the huge individual variation, impre-
cision in estimates and limited capacity in predicting the 
extreme ages of menopause (eg, it cannot identify those 
at risk of early menopause) means its clinical applicability 
in individual women is limited.34 Questions have also 
been raised about whether AMH adds substantive predic-
tive value over and above readily available patient charac-
teristics, such as age.9 35 Considering this, there were also 
several misleading corresponding statements about who 
the test is suitable for and possible actions to be taken 
in response to the test result. This was particularly the 
case for websites that recommended the test for women 
outside of fertility treatment settings18 (eg, women plan-
ning pregnancy now or in the future, women who are 
curious about their ovarian reserve) or websites that 
claimed the test assisted with reproductive life planning 
(when to start trying to conceive) or when to undertake 
elective egg freezing.
Consequently, many websites include incorrect, over-
stated or misleading statements about the ability of the 
AMH test to reliably predict fertility. This raises concerns 
that women who use the AMH test to plan timing of preg-
nancy may get a false sense of security about delaying 
pregnancy if their level is in the normal or high range, 
and give women with low readings unwarranted anxiety 
about their ability to conceive. This could in turn increase 
women’s perceived need to freeze their eggs,36 try to 
conceive earlier than they had planned or pursue fertility 
treatments when it may not be needed, increasing the 
risk of healthy individuals receiving unnecessary fertility 
care.37 While many clinics do not receive direct finan-
cial benefit from ordering the test, clinics would benefit 
from the outlined potential actions as a result of women 
getting the test result, such as seeing a fertility specialist, 
egg freezing or commencing fertility treatment. Although 
these findings may reflect the varied views held about the 
utility of the AMH test and mixed evidence supporting its 
use in practice, it likely increases confusion for women 
seeking information regarding the AMH test and perpetu-
ates unrealistic expectations. Given fertility clinic websites 
have been found to be a primary source of information 
for people seeking fertility treatments,38 it is essential the 
information provided is accurate and reflects the highest 
level of available evidence.20
Our findings of misleading or inaccurate information 
on fertility clinic websites are similar to recent studies 
evaluating the quality of website information regarding 
oocyte cryopreservation and of various interventions used 
in addition to standard IVF procedures.20 39 For example, 
a recent analysis of the quality of information about 
elective oocyte cryopreservation on Australian and New 
Zealand fertility clinic websites found that more than half 
scored poor, indicating that women are not receiving the 
information they need to make well- informed choices.39 
To make autonomous decisions, patients must be 
presented with accurate, balanced information regarding 
the risks, benefits and limitations. Websites that do not 
state limitations or include misleading statements are 
impeding consumer decision- making and placing a large 
burden on clinicians to dispel misconceptions.40 The 
decision to have an AMH test may appear to be empow-
ering; however, this rests on the false assumption that the 
test is an accurate predictor of fertility status.40
To our knowledge, this is the first study to rigorously 
and systematically assess publicly available AMH- related 
information for women using the well- established content 
analysis method, which involved a number of members 
of a multidisciplinary study team. The current study only 
included blogs from 2015, so older posts were excluded. 
This decision was made as the quality of reporting on the 
test before this time was poor and we felt it was not a fair 
judgement of the clinics’ current information. A limita-
tion of the study is that it is unclear how consumers would 
interpret the information. Future studies are needed to 
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assess how women interpret and respond to the informa-
tion captured. We also excluded non- text content, such as 
videos, which may have had more accurate information. 
Website content also changes over time, so a different 
set of reviewers at a later date might locate different 
information to what was captured. In addition, direct- to- 
consumer websites or fertility clinics in countries without 
accrediting bodies may have worse quality information, so 
replication in other settings is warranted.
In conclusion, some Australian and New Zealand 
fertility clinic websites contain a number of statements 
regarding the utility of the AMH test which are not 
supported by the evidence and are potentially misleading. 
Fertility clinics should provide information based on the 
best available evidence and be transparent about uncer-
tainties and limitations. In particular, the lack of utility of 
the AMH test for women without a diagnosis of infertility 
needs to be much clearer to prevent women having this 
test believing that it can accurately gauge their current 
and future fertility. These are high- stake decisions for 
women, so high- quality, accurate information to enable 
informed decision- making is essential.
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